Human Anti-HIV-1 gp41 Recombinant Antibody (clone 2F5)
CAT#: PABL-186
Recombinant Human Antibody (2F5) is capable of binding to MPER of HIV-1 gp41, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 gp41 mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 gp41 mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
Published Data
Tested Data
Figure 1 Binding of gp41 cluster II MAbs to anionic phospholipids.
SPR sensograms are shown for the binding of 100 μg/ml of 126-6, 167D, 98-6, 4E10, 2F5, and 13H11 MAbs to POPC-cardiolipin (25:75) (A) or POPC-POPS (25:75) (B) liposomes captured on a Biacore L1 chip.
Dennison, S. M., Anasti, K., Scearce, R. M., Sutherland, L., Parks, R., Xia, S. M.,... & Alam, S. M. (2011). Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. Journal of virology,85(3), 1340-1347.
Figure 2 Nonneutralizing human gp41 cluster II MAbs bind strongly to oligomeric gp140 Env proteins.
SPR sensograms are displayed for the binding of 98-6, 167D, 126-6, 2F5, and 13H11 MAbs to the ConB gp140 (A), ConS gp140 CFI (B), and JRFL gp140 (C) Env proteins immobilized on a Biacore CM5 chip.
Dennison, S. M., Anasti, K., Scearce, R. M., Sutherland, L., Parks, R., Xia, S. M.,... & Alam, S. M. (2011). Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. Journal of virology,85(3), 1340-1347.
Figure 3 Neutralization of the 2F5-resistant HIV-1JR2 mutant pseudovirus D664A by T20 in the presence and absence of 2F5 or D50.
Virus was preincubated with different concentrations of T20 in the presence or absence of a molar excess of either 2F5 or D50 (1 μM constant throughout) and then added to U87.CD4.CCR5 cells. Luciferase activity was measured after 72 h. The sequence of T20 is shown below the graph with the 2F5 epitope indicated, as well as the approximate region to which D50 binds, according to a previous study. Control experiments showed no effect of 1 μM D50 or 2F5 on the infectivity of the JR2 mutant D664A.
Dennison, S. M., Anasti, K., Scearce, R. M., Sutherland, L., Parks, R., Xia, S. M.,... & Alam, S. M. (2011). Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. Journal of virology,85(3), 1340-1347.
Figure 4 The Octet binding curves of wt 2F5 Mab to the three probes in solution are shown for the wt MPER peptide, the linked peptide, and the ES2 2F5-epitope scaffold. The experimental binding curves are shown in blue and the applied Languir 1:1 model fitting of the curves are shown in red. Representative binding curves of the CDRH3-length altered 2F5 variants r4 and e4 are shown below.
Guenaga, J., & Wyatt, R. T. (2012). Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS pathogens, 8(7), e1002806.
Figure 5 Alanine scanning of the 4E10 MPER region 669–673 and effects on recognition of 4E10, wt 2F5 and the CDRH3 and W/Y variants are shown. The bars represent fold-increase or -decrease in the binding constant (KD) of the Mabs to the alanine-substituted peptides compared to KDs for the wt MPER peptide. A positive bar indicates an affinity increase and a negative bar indicates an affinity decrease. The bars are color-coded for each ligand Mab. For context, the MPER residues comprising the 2F5 and 4E10 epitopes are shown and the residues 669–673 scanned by the alanine substitutions are as indicated.
Guenaga, J., & Wyatt, R. T. (2012). Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS pathogens, 8(7), e1002806.
Figure 6 Neutralizing activity of MPER-specific IgA1 on primary and laboratory HIV-1 strains. 4E10 and 2F5 were used as positive controls. Dose-dependent neutralization was performed within a concentration range of 0.156–10 mg/ml.
Benjelloun, F., Oruc, Z., Thielens, N., Verrier, B., Champier, G., Vincent, N.,... & Genin, C. (2016). First Membrane Proximal External Region–Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations. The Journal of Immunology, 1600309.
❮
❯
SDS-PAGE
Figure 1 Human Anti-HIV-1 gp41 Recombinant Antibody in SDS-PAGE analysis.
SDS-PAGE analysis of PABL-186 in reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol- reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates about 180 kDa.
SEC-HPLC
Figure 2 Human Anti-HIV-1 gp41 Recombinant Antibody in HPLC analysis.
HPLC analysis of PABL-186 shows the purity is>95%.
ELISA
Figure 3 Human Anti-HIV-1 gp41 Recombinant Antibody (clone 2F5) (PABL-186) in ELISA
ELISA analysis of PABL-186 was performed by coating with Recombinant HIV1 gp41 protein.
The secondary antibody: Goat Anti-Human IgG(H+L)-HRP
DB
Figure 4 Human Anti-HIV-1 gp41 Recombinant Antibody (clone 2F5) (PABL-186) in DB
Dot Blot analysis of PABL-186 was performed by coating with Recombinant HIV1 gp41 protein.
PABL-186 incubation concentration: 2ng/μL.
The secondary antibody: Goat Anti-Human IgG(H+L)-HRP
NC: Negative control PC: Positive control
❮
❯
Specifications
- Host Species
- Human
- Type
- Human IgG
- Species Reactivity
- HIV-1
- Clone
- 2F5
- Applications
- WB, Neut, FuncS
Product Property
- Purity
- >95% as determined by SDS-PAGE
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- The antibody was validated for Neut. For details, refer to published data.
Target
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for PABL-186. Click the button above to contact us or submit your feedback about this product.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABL-186, RRID: AB_3111635)
Copy citation
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "Clone 2F5"
- CAT
- Product Name
See other products for "HIV-1 gp41"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-486-S(P) | Recombinant Anti-HIV-1 gp41 Antibody scFv Fragment | FC, WB, FuncS | scFv |
| MRO-4045CQ-S(P) | Human Anti-HIV-1 gp41 Recombinant Antibody scFv Fragment (MRO-4045CQ-S(P)) | ELISA | Human scFv |
| MRO-4046CQ-S(P) | Human Anti-HIV-1 gp41 Recombinant Antibody scFv Fragment (MRO-4046CQ-S(P)) | Neut | Human scFv |
| MRO-4047CQ-S(P) | Human Anti-HIV-1 gp41 Recombinant Antibody scFv Fragment (MRO-4047CQ-S(P)) | Neut | Human scFv |
| MRO-4048CQ-S(P) | Human Anti-HIV-1 gp41 Recombinant Antibody (clone 126-50); scFv Fragment | ELISA | Human scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| PABL-185 | Human Anti-HIV-1 gp41 Recombinant Antibody (clone 8062) | WB, ELISA, FuncS | Human IgG |
| PABL-187 | Human Anti-HIV-1 gp41 Recombinant Antibody (clone 3BC176) | Neut, FuncS | Human IgG |
| PABL-188 | Human Anti-HIV-1 gp41 Recombinant Antibody (clone 3BC315) | Neut, FuncS | Human IgG |
| PABL-189 | Human Anti-HIV-1 gp41 Recombinant Antibody (clone m66) | Neut, FuncS | Human IgG |
| PABL-190 | Human Anti-HIV-1 gp41 Recombinant Antibody (PABL-190) | WB, ELISA, FuncS | Human IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MRO-074LC | Anti-HIV-1 gp41 Recombinant Antibody (W) | ELISA | Human antibody |
| MRO-093LC | Anti-HIV-1 gp41 Recombinant Antibody (clone 43) | ELISA | Human antibody |
| MRO-025LC-S(P) | Anti-HIV-1 gp41 Recombinant Antibody scFv Fragment (4E10-IgG3) | ELISA | Human antibody |
| MRO-026LC-S(P) | Anti-HIV-1 gp41 Recombinant Antibody scFv Fragment (4E10-IgG1) | ELISA | Human antibody |
| MRO-093LC-F(E) | Anti-HIV-1 gp41 Recombinant Antibody Fab Fragment (clone 43) | ELISA | Human antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MHC-LC746 | A*2402/HIV-1 gp41 (RYLKDQQLL) MHC Tetramer | FCM |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MRO-4063CQ | Human Anti-HIV-1 gp41 Recombinant Antibody (MRO-4063CQ) | FC | Human IgM |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MRO-4045CQ-F(E) | Human Anti-HIV-1 gp41 Recombinant Antibody Fab Fragment (MRO-4045CQ-F(E)) | ELISA | Human Fab |
| MRO-4046CQ-F(E) | Human Anti-HIV-1 gp41 Recombinant Antibody Fab Fragment (MRO-4046CQ-F(E)) | Neut | Human Fab |
| MRO-4047CQ-F(E) | Human Anti-HIV-1 gp41 Recombinant Antibody Fab Fragment (MRO-4047CQ-F(E)) | Neut | Human Fab |
| MRO-4048CQ-F(E) | Human Anti-HIV-1 gp41 Recombinant Antibody (clone 126-50); Fab Fragment | ELISA | Human Fab |
| MRO-4049CQ-F(E) | Human Anti-HIV-1 gp41 Recombinant Antibody (clone 126-6 (SZ-126.6)); Fab Fragment | ELISA, RIA, WB | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0325-FY129 | Human Anti-HIV-1 gp41 (clone A2) scFv-Fc Chimera | Neut, ADCC | Human IgG1, scFv-Fc |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0625-XY41 | Human Anti-HIV-1 gp41 Vaccinal Antibody (VS-0625-XY41) | ELISA | Human IgG |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: FC, Cyt, Stim, PP, Agonist
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: Neut, ELISA, FuncS
Application: Neut, FC
Application: WB, ELISA, FuncS, IB, FC, SPR, Apop
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, IHC, FC, IP, IF, FuncS
-2.png)
Application: WB, ELISA, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
